Fengsheng Chen

606 total citations
44 papers, 461 citations indexed

About

Fengsheng Chen is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Fengsheng Chen has authored 44 papers receiving a total of 461 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 10 papers in Pulmonary and Respiratory Medicine and 8 papers in Oncology. Recurrent topics in Fengsheng Chen's work include Ferroptosis and cancer prognosis (4 papers), Cancer Mechanisms and Therapy (4 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Fengsheng Chen is often cited by papers focused on Ferroptosis and cancer prognosis (4 papers), Cancer Mechanisms and Therapy (4 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Fengsheng Chen collaborates with scholars based in China, United States and Macao. Fengsheng Chen's co-authors include Rongcheng Luo, Aimin Li, Wan Zhang, Qian Geng, Junyi Zhang, Hua Xiao, Shenglan Gao, Chengliang Zhang, Rong Li and Feiye Liu and has published in prestigious journals such as Cancer Cell, Oncogene and Biochemical and Biophysical Research Communications.

In The Last Decade

Fengsheng Chen

41 papers receiving 452 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fengsheng Chen China 13 245 104 97 89 51 44 461
Jufang Chi China 15 288 1.2× 86 0.8× 77 0.8× 79 0.9× 48 0.9× 26 579
Shenglin Ma China 13 264 1.1× 179 1.7× 115 1.2× 145 1.6× 39 0.8× 33 579
Arunima Shilpi India 13 428 1.7× 104 1.0× 120 1.2× 97 1.1× 33 0.6× 17 726
Guanghui Wang China 13 265 1.1× 71 0.7× 63 0.6× 194 2.2× 39 0.8× 28 526
Young‐Lan Park South Korea 17 382 1.6× 171 1.6× 59 0.6× 129 1.4× 34 0.7× 49 659
Yangwei Xu China 6 231 0.9× 117 1.1× 111 1.1× 136 1.5× 26 0.5× 12 440
Ronglin Yan China 11 235 1.0× 91 0.9× 94 1.0× 89 1.0× 56 1.1× 24 531
Lo‐Lin Tsai Taiwan 12 221 0.9× 171 1.6× 42 0.4× 149 1.7× 29 0.6× 15 456
Zhirong Jia China 14 316 1.3× 89 0.9× 109 1.1× 199 2.2× 62 1.2× 23 632
Zhenkun Xia China 12 238 1.0× 85 0.8× 54 0.6× 114 1.3× 44 0.9× 34 407

Countries citing papers authored by Fengsheng Chen

Since Specialization
Citations

This map shows the geographic impact of Fengsheng Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengsheng Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengsheng Chen more than expected).

Fields of papers citing papers by Fengsheng Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengsheng Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengsheng Chen. The network helps show where Fengsheng Chen may publish in the future.

Co-authorship network of co-authors of Fengsheng Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Fengsheng Chen. A scholar is included among the top collaborators of Fengsheng Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengsheng Chen. Fengsheng Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chen, Fengsheng, et al.. (2025). Ammonium tetrathiomolybdate attenuates acetaminophen-induced acute liver failure by inhibiting the TRPV4/Calcium/NF-κB signaling pathway. Biochemical Pharmacology. 237. 116917–116917. 2 indexed citations
3.
Chen, Yan, Fengsheng Chen, Lishan Chen, et al.. (2024). Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor. Phytomedicine. 129. 155688–155688. 7 indexed citations
4.
He, Weili, Yan Chen, Lihong Li, et al.. (2024). Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction. Journal of Advanced Research. 69. 399–411. 10 indexed citations
5.
6.
7.
8.
9.
Chen, Fengsheng, et al.. (2023). Immune-Cell-Based Therapy for COVID-19: Current Status. Viruses. 15(11). 2148–2148. 3 indexed citations
10.
Zhang, Jiakang, Dayong Zheng, Yue Luo, et al.. (2023). Identification of Prognosis-Related Oxidative Stress Model with Immunosuppression in HCC. Biomedicines. 11(3). 695–695. 4 indexed citations
11.
Zhang, Linmeng, Chen Yang, Xiaowen Huang, et al.. (2022). A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment. BMC Cancer. 22(1). 613–613. 2 indexed citations
12.
Luo, Yue, et al.. (2021). LncRNA SNHG17 Contributes to Proliferation, Migration, and Poor Prognosis of Hepatocellular Carcinoma. Canadian Journal of Gastroenterology and Hepatology. 2021(1). 9990338–9990338. 16 indexed citations
13.
Geng, Qian, et al.. (2021). SHP-1 acts as a tumor suppressor by interacting with EGFR and predicts the prognosis of human breast cancer. Cancer Biology and Medicine. 19(4). 468–485. 16 indexed citations
14.
Zhang, Jiakang, Na Qi, Xinhui Liu, et al.. (2021). EFNA4 promotes cell proliferation and tumor metastasis in hepatocellular carcinoma through a PIK3R2/GSK3β/β-catenin positive feedback loop. Molecular Therapy — Nucleic Acids. 25. 328–341. 21 indexed citations
15.
Zhang, Wan, et al.. (2018). Knockout of NCOA5 impairs proliferation and migration of hepatocellular carcinoma cells by suppressing epithelial-to-mesenchymal transition. Biochemical and Biophysical Research Communications. 500(2). 177–183. 21 indexed citations
16.
Lü, Wenli, et al.. (2016). Analysis of clinical features and related genes variation in 41 girls with McCune-Albright syndrome. Zhonghua neifenmi daixie zazhi. 32(12). 995–998. 1 indexed citations
17.
Hu, Yingying, Fengsheng Chen, Feiye Liu, et al.. (2015). Overexpression of TIP30 inhibits the growth and invasion of glioma cells. Molecular Medicine Reports. 13(1). 605–612. 13 indexed citations
18.
Zhang, Junyi, et al.. (2014). TIP30 nuclear translocation negatively regulates EGF-dependent cyclin D1 transcription in human lung adenocarcinoma. Cancer Letters. 354(1). 200–209. 10 indexed citations
19.
Gao, Shenglan, Aimin Li, Feiye Liu, et al.. (2013). NCOA5 Haploinsufficiency Results in Glucose Intolerance and Subsequent Hepatocellular Carcinoma. Cancer Cell. 24(6). 725–737. 51 indexed citations
20.
Chen, Fengsheng, Xi Luo, Jinbiao Zhang, Lu Yang, & Rongcheng Luo. (2009). Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib. Medical Oncology. 27(3). 950–957. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jufang Chi Breakdown of academic impact, for papers by Shenglin Ma Breakdown of academic impact, for papers by Arunima Shilpi Breakdown of academic impact, for papers by Guanghui Wang Breakdown of academic impact, for papers by Young‐Lan Park Breakdown of academic impact, for papers by Yangwei Xu Breakdown of academic impact, for papers by Ronglin Yan Breakdown of academic impact, for papers by Lo‐Lin Tsai Breakdown of academic impact, for papers by Zhirong Jia Breakdown of academic impact, for papers by Zhenkun Xia
Rankless by CCL
2026